• Home
  • About EpiPen® and Its Authorized Generic

History doesn’t always prepare us for the future.

Anaphylaxis is unpredictable. The severity of future anaphylactic reactions cannot be accurately predicted based on the level of sIgE, the size of the skin prick test wheal or the severity of past reaction.1,2 In addition:

  • Up to 20% of children will not have cutaneous symptoms during an anaphylactic reaction3
  • Involvement of body organ systems in anaphylaxis varies among patients, and even in the same patient from one allergic reaction to another4-6

EpiPen® and EpiPen Jr® (epinephrine injection, USP), and their authorized generic auto-injectors

Mylan’s branded and authorized generic auto-injectors are used for the emergency treatment of the signs and symptoms of anaphylaxis, including pruritus, urticaria, angioedema, flushing, syncope, tachycardia and dyspnea due to laryngeal spasm and/or a decrease in blood pressure. Anaphylaxis can be caused by triggers such as food, biting or stinging insects, medicines, latex or even radiocontrast media and exercise.5-9

EpiPen® Auto-Injector has been the most prescribed brand of self-injectable epinephrine for more than 25 years.10

In that time, nearly 77 million EpiPen® Auto-Injectors have been dispensed.10

Watch a step-by-step video for patients on how to use the EpiPen® Auto-Injector and its authorized generic.

Step-by-Step Instructions

Simple by design and familiar to millions10—
EpiPen® is designed for ease of use in emergencies

Mylan’s authorized generic is identical to EpiPen® in design and function—only the name on the label is different

Features include8:

EpiPen® (epinephrine injection, USP) Auto-Injector

Access to two for your patients

EpiPen®, EpiPen Jr® and their authorized generic auto-injectors are available in cartons of two.8,9 Up to 20% of patients need additional doses due to a biphasic reaction or protracted symptoms1,6.According to national food allergy guidelines, it is recommended to have access to two epinephrine auto-injectors, which provides two sequential doses if needed during an anaphylactic reaction.1 Each carton also includes a Trainer, which may be valuable in promoting patient familiarity with the administration of EpiPen® Auto-Injector or its authorized generic.8,9

Share This Site

Special Offers

Mylan offers Access and Savings Programs for eligible patients.

Learn more here »

There’s only one recommended first line treatment for anaphylaxis.

Epinephrine, not antihistamines »

More Important Safety Information

EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EpiPen® and EpiPen Jr® should only be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into buttock, or into digits, hands, or feet. Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are indicated in the emergency treatment of Type I allergic reactions, including anaphylaxis, to allergens, idiopathic and exercise-induced anaphylaxis, and in patients with a history or increased risk of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to body weight.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-796-9526.

References

  1. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6 Suppl):S1-S58.
  2. Simons FE. Anaphylaxis: recent advances in assessment and treatment. J Allergy Clin Immunol. 2009;124(4):625-636.
  3. Järvinen KM, Celestin J. Anaphylaxis avoidance and management: educating patients and their caregivers. J Asthma Allergy. 2014;7:95-104.
  4. Dinakar C. Anaphylaxis in children: current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep. 2012;12(6):641-649.
  5. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis­—a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384.
  6. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S161-S181.
  7. Volcheck GW. Clinical Allergy: Diagnosis and Management. Rochester, MN: Mayo Foundation for Medical Education and Research; 2009.
  8. EpiPen [prescribing & patient information]. Morgantown, WV: Mylan Specialty L.P.; 2017.
  9. Epinephrine Injection, USP [prescribing & patient information]. Morgantown, WV: Mylan Specialty L.P.; 2017.
  10. Data on file: IMS Report (1987-May 2016).
  11. Ram FSF, Hoare K, Arroll B, Hoare S. Epinephrine self-administration in anaphylactic emergencies: comparison of commonly available autoinjectors. J Asthma Allergy Educ. 2012;3(4):178-181.
  • About Anaphylaxis
  • About EpiPen® and Its Authorized Generic
  • For Healthcare Partners
  • Access to EpiPen® and Its Authorized Generic
    • EpiPen® & EpiPen Jr® (epinephrine injection, USP) Auto-Injectors 0.3/0.15mg

    You are now leaving Mylan Specialty's website.

    The website you are about to access is not owned or controlled by Mylan Specialty.

    MYLAN SPECIALTY ASSUMES NO RESPONSIBILITY FOR, AND MAKES NO REPRESENTATION AS TO THE ACCURACY OF, ANY CONTENT CONTAINED ON THE WEBSITE YOU ARE ABOUT TO ACCESS.

    OK
    Cancel

    This site is intended for US healthcare professionals.

    If you are a patient, please check out our site for patients.

    Go to Patient Site
    Proceed to Healthcare Professional Site